Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
The primary objective of this study is to compare the efficacy of tarlatamab plusdurvalumab with durvalumab alone on prolonging overall survival (OS).
Description for laymen
The primary objective of this study is to compare the efficacy of tarlatamab plusdurvalumab with durvalumab alone on prolonging overall survival (OS).
JSON Data
{
"short_title": "DeLLphi-305 20200041",
"data_mode": "900",
"data_mode_number": "000002375",
"official_title": "A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": "NCT06211036",
"eudract_number": null,
"general_contact_email": null,
"general_contact_phone": null,
"hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke",
"description_laie_de": "Das prim\u00e4re Ziel dieser Studie ist der Vergleich der Wirksamkeit von Tarlatamab plus Durvalumab mit Durvalumab allein im Hinblick auf die Verl\u00e4ngerung des Gesamt\u00fcberlebens (OS).",
"description_laie_en": "The primary objective of this study is to compare the efficacy of tarlatamab plusdurvalumab with durvalumab alone on prolonging overall survival (OS).",
"description_expert_de": "Das prim\u00e4re Ziel dieser Studie ist der Vergleich der Wirksamkeit von Tarlatamab plus Durvalumab mit Durvalumab allein im Hinblick auf die Verl\u00e4ngerung des Gesamt\u00fcberlebens (OS).",
"description_expert_en": "The primary objective of this study is to compare the efficacy of tarlatamab plusdurvalumab with durvalumab alone on prolonging overall survival (OS).",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "III",
"main_cat_id": 10,
"sub_cat_id": 51
}
